<DOC>
	<DOCNO>NCT02272413</DOCNO>
	<brief_summary>The objective phase III trial establish statistical equivalence term efficacy ( best overall response rate [ ORR ] , proportion patient complete response [ CR ] plus partial response [ PR ] ) 18 week first-line treatment BI 695502 plus chemotherapy versus Avastin® plus chemotherapy follow maintenance monotherapy either BI 695502 Avastin® .</brief_summary>
	<brief_title>Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy Patients With Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Inclusion criterion : Adult patient age &gt; =18 year histologically cytologically confirm advanced nonsquamous nonsmall cell lung cancer ( nsNSCLC ) . Mixed tumor categorize accord predominant histology . Note : NSCLC predominantly nonsquamous . Recurrent metastatic disease ( Stage IV ) indication therapy paclitaxel + carboplatin + Avastin® . Patients harbor tumor unknown without activate epidermal growth factor receptor ( EGFR ) / anaplastic lymphoma receptor tyrosine kinase ( ALK ) mutation maybe include provide chemotherapy standard care . At least one measurable lesion accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 base independent central review . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 1 . Adequate hepatic , renal , bone marrow function : Life expectancy &gt; 6 month base clinical judgment . Further inclusion criterion apply . Exclusion criterion : Prior therapy monoclonal antibody small molecule inhibitor Vascular Endothelial Growth Factor ( VEGF ) VEGF receptor , include Avastin® . Prior systemic therapy metastatic disease . Prior systemic anticancer therapy radiotherapy locally advance nsNSCLC complete &lt; 12 month prior Screening . Previous malignancy NSCLC last 5 year except basal cell cancer skin preinvasive cancer cervix . Symptomatic brain metastasis . Diagnosis small cell carcinoma lung , squamous cell carcinoma lung , NSCLC specify ( NS ) NSCLC otherwise specify ( NOS ) . Any unresolved toxicity &gt; Common Toxicity Criteria Grade 1 ( except alopecia ) previous anticancer therapy ( include radiotherapy ) . History evidence inherit bleed diathesis coagulopathy risk bleeding . Thrombotic hemorrhagic event = &lt; 6 month prior Screening . Further exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>